Diabetics
Adamco Products
Pharmacological CATEGORY:
Combination of two oral Hypoglycemic drugs: Gliclazide ( of the Sulfonylurea class ) and  Metformin hydrochloride.

COMPOSITIONS:
Each tablet contains: 80 mg gliclazide and 500 mg metformin hydrochloride.

MECHANIZEM OF ACTION:
Adamicron plus combines two hypoglycemic agents with complementary mechanisms of action.
  • Gliclazide: β-cell-selective sulfonylurea which provides global metabolic and vascular treatment of type 2 diabetic patients. It reduces blood glucose levels by correcting both defective insulin secretion and peripheral insulin resistance. This occurs by the closure of potassium channels in β-cells of the pancreas, subsequently opening calcium channels and increasing intracellular calcium and inducing insulin release. It also increases the sensivity of β-cells to glucose. It restores peripheral insulin sensitivity by decreasing hepatic glucose production and increasing glucose clearance. It has an anti-platelet adhesive activity, and reduces the levels of free radicals (anti-oxidnat properties), thereby preventing vascular complications.
  • Metformin hydrochloride: hypoglycemic agent, Improves glucose tolerance in patients with type 2 diabetes by lowering both basal and postprandial plasma glucose. It decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. It normalizes weight in overweight patients.

PHARMACOKINETICS:
Metforin hydrochloride: The absolute bioavailability is approximately 50-60% .GIT absorption is complete within 6 hours of administration. Steady state plasma concentrations are reached within 24-48 hours. Meformin is not bound to plasma proteins and is excreted unchanged. 95% of the absorbed drug is eliminated during primary elimination phase having half-life of 6 hours. Rest of the 5% is eliminated during slow terminal elimination phase with a mean half-life of 20 hours. 40-60% of the dose is excreted in the urine and 30% with feces
Gliclazide: reaches maximum plasma concentration within 2-8 hours. Steady state concentrations are achieved after 2 days of administration. The volume of distribution is low due to extensive protein binding (85-97%). Half-life varies from 8.1 to 20.5 hours.  Glicazide is extensively metabolized to 7 metabolites predominantly excreted in the urine (60-70% of the doses). The remaining 10-20% is excreted in the feces.

DOSAGE AND ADMINISTRATION:
1-2 tablets once or twice daily. The maximum daily dose is 4 tablets. In the majority of cases, glycemic control is obtained with one tablet twice daily taken with meals.


read more